e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Does cost-effectiveness go together with best quality of treatment? New drivers in medicine
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The impact and costs of reimbursed smoking cessation using varenicline in Denmark
J. Dollerup, P. B. Poulsen, P. Tønnesen (Ballerup, Gentofte, Denmark)
Source:
Annual Congress 2010 - Does cost-effectiveness go together with best quality of treatment? New drivers in medicine
Session:
Does cost-effectiveness go together with best quality of treatment? New drivers in medicine
Session type:
Oral Presentation
Number:
5181
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Dollerup, P. B. Poulsen, P. Tønnesen (Ballerup, Gentofte, Denmark). The impact and costs of reimbursed smoking cessation using varenicline in Denmark. Eur Respir J 2010; 36: Suppl. 54, 5181
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Costs and benefits accruing from smoking cessation with varenicline
Source: Annual Congress 2007 - Smoking cessation
Year: 2007
Cost-effectiveness of varenicline for smoking cessation in the Netherlands
Source: Eur Respir J 2007; 30: Suppl. 51, 247s
Year: 2007
The cost-effectiveness of smoking cessation interventions. Accounting for medical costs in longer life expectancies
Source: Annual Congress 2006 - How to treat tobacco smokers
Year: 2006
Annual budgetary impact of varenicline as part of a smoking cessation strategy in Greece
Source: International Congress 2015 – Emerging data on (e-)cigarettes and their health hazards
Year: 2015
Cost effectiveness of retreatment with varenicline compared to other commonly used smoking cessation interventions
Source: International Congress 2015 – Emerging data on (e-)cigarettes and their health hazards
Year: 2015
Effectiveness of varenicline treatment in a smoking cessation clinic
Source: Annual Congress 2009 - Epidemiology of smoking and smoking cessation
Year: 2009
Causes of quitting treatment with varenicline in a smoking cessation clinic
Source: Annual Congress 2009 - Epidemiology of smoking and smoking cessation
Year: 2009
How much does smoking cessation (SC) medications impacts on the income of the attendees of a smoking cessation clinic? A cross-sectional study
Source: International Congress 2016 – Emerging issues in smoking cessation and tobacco products
Year: 2016
Does reimbursement increase smoking cessation rate? – Outcomes of ²stop smoking² national program in a smoking cessation center.
Source: Annual Congress 2008 - Towards smoking cessation
Year: 2008
Misjudgements among hospital physicians regarding smoking and smoking cessation
Source: Annual Congress 2009 - Smoking cessation
Year: 2009
Smoking habits and the utilization of a smoking cessation service in the UK
Source: Annual Congress 2009 - Smoking cessation
Year: 2009
The costs of smoking and the economics of smoking cessation
Source: Eur Respir Mon; 2008: 42: 23–34
Year: 2008
The smoking cessation center and three-years impact on smoking among pneumology staff
Source: Annual Congress 2009 - Tobacco and health professionals
Year: 2009
Predicted health and economic benefits of smoking cessation incorporating multiple quit attempts over a lifetime
Source: Annual Congress 2011 - Smoking cessation science
Year: 2011
Efficacy of Zyban as smoking cessation aid for medical staff
Source: Eur Respir J 2001; 18: Suppl. 33, 447s
Year: 2001
Electronic cigarettes knowledge and use among smokers attending an intensive smoking cessation intervention programme
Source: International Congress 2018 – Epidemiology of the use of traditional and emerging tobacco products and e-cigarettes
Year: 2018
How does reimbursement status affect the smoking cessation interventions?
Source: International Congress 2018 – Tobacco use and cessation interventions in patients with respiratory, cardiovascular and mental health problems and other populations
Year: 2018
Smoking cessation in COPD, modelling the cost effectiveness of minimal counseling or intensive counseling plus bupropion
Source: Eur Respir J 2004; 24: Suppl. 48, 463s
Year: 2004
Half of oral NRT delivered to smoker hospital staff are not use for tobacco cessation but for long term substitution
Source: Annual Congress 2013 –Smoking cessation for healthy and non-healthy smokers
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept